Innovent Showcases Preclinical Data of its First-in-Class IL-6 x TL1A Bispecific Antibody at ACR Convergence 2026

Markets PR Newswire By PR Newswire 13 Nov 2026 00:00 1 min read
Innovent Showcases Preclinical Data of its First-in-Class IL-6 x TL1A Bispecific Antibody at ACR Convergence 2026

PALO ALTO, Calif. and SUZHOU, China, Nov. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular,...

Covered in this story

Call it yourself

No calls on $ACR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.

Make the first call on Acres Commercial Realty Corp →
Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.